[go: up one dir, main page]

SE9302308D0 - Protein formulation - Google Patents

Protein formulation

Info

Publication number
SE9302308D0
SE9302308D0 SE19939302308A SE9302308A SE9302308D0 SE 9302308 D0 SE9302308 D0 SE 9302308D0 SE 19939302308 A SE19939302308 A SE 19939302308A SE 9302308 A SE9302308 A SE 9302308A SE 9302308 D0 SE9302308 D0 SE 9302308D0
Authority
SE
Sweden
Prior art keywords
pct
subcutaneous
factor viii
intramuscular
intradermal administration
Prior art date
Application number
SE19939302308A
Other languages
English (en)
Other versions
SE504074C2 (sv
SE9302308L (sv
Inventor
*Spira Jack
*Widlund Lars
*Oesterberg Thomas
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9302308(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9302308A priority Critical patent/SE504074C2/sv
Publication of SE9302308D0 publication Critical patent/SE9302308D0/sv
Priority to ZA942035A priority patent/ZA942035B/xx
Priority to MX9402339A priority patent/MX9402339A/es
Priority to CA002163112A priority patent/CA2163112C/en
Priority to DE69432179T priority patent/DE69432179T3/de
Priority to PT94915722T priority patent/PT710114E/pt
Priority to ES94915722T priority patent/ES2193159T5/es
Priority to EP94915722A priority patent/EP0710114B2/en
Priority to SE9401105A priority patent/SE9401105D0/sv
Priority to JP50398795A priority patent/JP3827713B2/ja
Priority to AT94915722T priority patent/ATE233099T1/de
Priority to US08/564,161 priority patent/US5972885A/en
Priority to AU67627/94A priority patent/AU6762794A/en
Priority to PCT/SE1994/000297 priority patent/WO1995001804A1/en
Priority to DK94915722.6T priority patent/DK0710114T4/da
Publication of SE9302308L publication Critical patent/SE9302308L/sv
Publication of SE504074C2 publication Critical patent/SE504074C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9302308A 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering SE504074C2 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE9302308A SE504074C2 (sv) 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering
ZA942035A ZA942035B (en) 1993-07-05 1994-03-23 Protein formulation
MX9402339A MX9402339A (es) 1993-07-05 1994-03-30 Formulacion de proteina.
DK94915722.6T DK0710114T4 (da) 1993-07-05 1994-03-31 Koagulationsfaktor VIII-formulering
PCT/SE1994/000297 WO1995001804A1 (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation
EP94915722A EP0710114B2 (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation
AT94915722T ATE233099T1 (de) 1993-07-05 1994-03-31 Eine formulierung des gerinnungsfaktors viii
PT94915722T PT710114E (pt) 1993-07-05 1994-03-31 Formulacao do factor viii de coagulacao
ES94915722T ES2193159T5 (es) 1993-07-05 1994-03-31 Una formulación de factor de coagulación viii.
CA002163112A CA2163112C (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation
SE9401105A SE9401105D0 (sv) 1993-07-05 1994-03-31 Formulation
JP50398795A JP3827713B2 (ja) 1993-07-05 1994-03-31 凝固因子ｖｉｉｉからなる医薬製剤
DE69432179T DE69432179T3 (de) 1993-07-05 1994-03-31 Eine formulierung des gerinnungsfaktors viii
US08/564,161 US5972885A (en) 1993-07-05 1994-03-31 Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives
AU67627/94A AU6762794A (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302308A SE504074C2 (sv) 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering

Publications (3)

Publication Number Publication Date
SE9302308D0 true SE9302308D0 (sv) 1993-07-05
SE9302308L SE9302308L (sv) 1995-01-06
SE504074C2 SE504074C2 (sv) 1996-11-04

Family

ID=20390516

Family Applications (2)

Application Number Title Priority Date Filing Date
SE9302308A SE504074C2 (sv) 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9401105A SE9401105D0 (sv) 1993-07-05 1994-03-31 Formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9401105A SE9401105D0 (sv) 1993-07-05 1994-03-31 Formulation

Country Status (14)

Country Link
US (1) US5972885A (sv)
EP (1) EP0710114B2 (sv)
JP (1) JP3827713B2 (sv)
AT (1) ATE233099T1 (sv)
AU (1) AU6762794A (sv)
CA (1) CA2163112C (sv)
DE (1) DE69432179T3 (sv)
DK (1) DK0710114T4 (sv)
ES (1) ES2193159T5 (sv)
MX (1) MX9402339A (sv)
PT (1) PT710114E (sv)
SE (2) SE504074C2 (sv)
WO (1) WO1995001804A1 (sv)
ZA (1) ZA942035B (sv)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9502285D0 (sv) 1995-06-22 1995-06-22 Pharmacia Ab Improvements related to injections
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
JP2002518354A (ja) * 1998-06-16 2002-06-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ 糖硫酸ペプチド、その合成方法および使用方法
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7977460B2 (en) * 2003-05-19 2011-07-12 National Institute For Biological Standards And Control Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
CN1266144C (zh) * 2003-09-01 2006-07-26 上海凯曼生物科技有限公司 黄芩甙和黄芩甙元的用途和剂型
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
DE102004005095A1 (de) 2004-01-27 2005-09-22 Coty B.V. Kosmetische Zusammensetzung mit wasserbeständiger Parfümkomponente
WO2005107776A1 (en) 2004-05-03 2005-11-17 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
ES2633916T3 (es) 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
TWI264608B (en) * 2005-04-08 2006-10-21 Delta Electronics Inc Light tunnel module
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP2486936A1 (en) 2007-06-13 2012-08-15 CSL Behring GmbH A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
TWI626057B (zh) 2009-06-09 2018-06-11 普龍製藥有限責任公司 血紅素組成物
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
JP6250282B2 (ja) * 2009-08-20 2017-12-20 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
DK2506868T3 (da) 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
DK2591006T3 (da) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
CN103209992A (zh) * 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
MY165089A (en) 2010-11-05 2018-02-28 Baxalta Inc A new variant of antihemophilic factor viii having increased specific activity
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
EP2709648A4 (en) 2011-05-19 2015-04-08 Geysen Hendrik M COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
PL3513804T3 (pl) 2011-07-08 2022-07-11 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN103889445A (zh) 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
PL2802668T3 (pl) 2012-01-12 2019-03-29 Bioverativ Therapeutics Inc. Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
RS59876B1 (sr) 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
WO2014176125A1 (en) * 2013-04-22 2014-10-30 The Scripps Research Institute Methods and compositions for treating bleeding disorders
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
KR102714760B1 (ko) 2013-06-28 2024-10-11 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US10251940B2 (en) 2014-06-06 2019-04-09 Octapharma Ag Preparation comprising factor VIII and Von Willebrand factor peptides
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US10189888B2 (en) 2015-11-13 2019-01-29 Baxalta Incorporated Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
SG11201804064WA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MY203184A (en) 2017-08-09 2024-06-13 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
EP3746136A1 (en) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
UY38160A (es) 2018-04-04 2019-11-29 Sigilon Therapeutics Inc Partículas implantables y métodos relacionados
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CA3106590A1 (en) 2018-07-16 2020-01-23 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) * 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
FI86885C (sv) * 1984-04-20 1992-10-26 Genentech Inc Förfarande för framställning av human rekombinantfaktor VIII och nukle insyrasekvenser och vektorer använd därtill
DE3683980D1 (de) * 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
IL83192A (en) * 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5204323B1 (en) * 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
DE4111393A1 (de) † 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
GB9122609D0 (en) † 1991-10-24 1991-12-04 Brownlee George G Improvements relating to the treatment of haemophilia
GB9211538D0 (en) * 1992-06-01 1992-07-15 Blake David R Antiinflammatory agent
SK282483B6 (sk) † 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
WO1994011013A1 (en) * 1992-11-13 1994-05-26 Duke University Chimeric blood coagulation proteins
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation

Also Published As

Publication number Publication date
JPH09500624A (ja) 1997-01-21
SE9401105D0 (sv) 1994-03-31
ES2193159T3 (es) 2003-11-01
DE69432179T2 (de) 2003-07-24
MX9402339A (es) 1995-01-31
DK0710114T3 (da) 2003-06-23
ES2193159T5 (es) 2011-07-29
SE504074C2 (sv) 1996-11-04
AU6762794A (en) 1995-02-06
CA2163112A1 (en) 1995-01-19
US5972885A (en) 1999-10-26
PT710114E (pt) 2003-06-30
WO1995001804A1 (en) 1995-01-19
SE9302308L (sv) 1995-01-06
ATE233099T1 (de) 2003-03-15
ZA942035B (en) 1995-01-05
DE69432179D1 (de) 2003-04-03
DE69432179T3 (de) 2012-01-19
EP0710114B2 (en) 2011-03-16
EP0710114A1 (en) 1996-05-08
EP0710114B1 (en) 2003-02-26
DK0710114T4 (da) 2011-07-11
CA2163112C (en) 2007-08-07
JP3827713B2 (ja) 2006-09-27

Similar Documents

Publication Publication Date Title
SE9302308D0 (sv) Protein formulation
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
ATE383168T1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
EP1719522B1 (en) Medicinal composition comprising TCF-II
DE69921348D1 (de) Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
Connolly et al. Local anaesthetic agents in surgery for ingrown toenail

Legal Events

Date Code Title Description
NUG Patent has lapsed